Onco-Targets – Making loss of SFRP tumour suppressor function druggable
The invention discloses molecules, which are activated,
when function of Secreted Fizzled Related Protein 1 (SFRP1) is lost. SFRP1 is known to have tumour suppressor function and its loss is associated to tumour progression and poor survival. Access to the signalling pathways regulated by SFRP1 leads to novel targets for cancer therapy and diagnosis. Such druggable targets open the route to screening of small molecules and design of monoclonal antibodies, thereby enabling the development of innovative oncological treatments as well as new diagnostic markers.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Superradiant atoms could push the boundaries of how precisely time can be measured
Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…
Ion thermoelectric conversion devices for near room temperature
The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…
